FDA to require vision loss warning on GLP-1 drug labels
2026-11-11 from globalnews.ca
GLP-1 drugs such as Ozempic and Wegovy prescribed in the U.S. will contain a new warning about a possible but rare side effect that can lead to permanent vision loss, the Food and Drug Administration (FDA) announced Monday.
The FDA will require the risk to be printed on the labelling of all GLP-1 drugs which are used to treat obesity, diabetes and a range of medical conditions, and can be injected or taken in pill form, including medications such as Zepbound and Mounjaro.
Read more here